Reaffirmation of Istin's Therapeutic Benefits to Patients After Initial Results Of Large Hypertension Study, Pfizer Says
Landmark Hypertension Study Stopped Earlier Than Expected Due to Reductions in Cardiovascular Death and All Cause Mortality
(I-Newswire) - Preliminary results of a large UK and Scandinavian hypertension clinical trial showed that patients receiving treatment based on the calcium channel blocker Istin ( amlodipine besylate, Pfizer ) experienced significant reductions in cardiovascular mortality and all cause mortality, and also had significantly fewer heart attacks and strokes compared to patients receiving a beta-blocker based regimen ( one of the current mainstays of UK treatment ). These initial data reaffirm the cardiovascular benefits of Istin, and were presented today at the annual American College of Cardiology meeting in Orlando, Florida.
Involving nearly 20,000 patients with high blood pressure, the Anglo-Scandinavian Cardiac Outcomes Trial ( ASCOT ) was designed to compare the effects of a Istin-based regimen versus a standard beta-blocker based regimen in reducing cardiac events in patients with hypertension and multiple cardiovascular risk factors. The trial was stopped early because preliminary data showed that patients receiving the Istin- based regimen demonstrated a 25 percent reduction in cardiovascular death and a 15 percent reduction in total mortality. These patients experienced a reduction in the primary endpoint ( fatal coronary heart disease and non-fatal heart attack ) of 10 percent, which did not reach statistical significance. In addition, they showed significant reductions in stroke, coronary events and they were also less likely to develop diabetes compared to patients taking the beta-blocker based regimen.
In the Istin based regimen, patients received the ACE-inhibitor perindopril and the alpha-blocker Cardura XL ( doxazosin GITS ) as add-on therapy if additional blood pressure control was needed. Patients receiving the beta-blocker based regimen atenolol, received a diuretic and Cardura XL ( doxazosin GITS ), if needed.
Funded by Pfizer, ASCOT is an investigator-initiated trial coordinated by an independent steering committee. The study began in 1998 and enrolled patients in the United Kingdom, Ireland, Sweden, Norway, Denmark, Finland and Iceland. In December 2004, the independent ASCOT steering committee endorsed the recommendation to stop the trial early due to favorable benefits demonstrated by patients in the Norvasc-based regimen.
“It is clear, based on these preliminary ASCOT results as well as previous studies that an Istin based blood-pressure lowering treatment regimen results in cardiovascular benefits for patients with high blood pressure” said Dr. Joseph Feczko, chief medical officer at Pfizer. “We look forward to seeing the final study results.”
Gareth Field Account Executive 35-41 Folgate Street London E1 6BX Tel: 020 7611 3668
If you have questions regarding information in this press release contact the company listed below. I-Newswire.com is a press release service and not the author of this press release. The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies / PR Agencies submit their press releases once per week/month or quarter, make sure check the official company website for accurate release dates as our site displays the I-Newswire.com distribution date only. We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for inaccuracies or omissions in that information or for actions taken in reliance on that information.
Immerse yourself in mystery and magic with two exciting new casual games from Focus Multimedia and Big Fish Games Studios, one of the world’s leading casual game developers. Hidden Expedition Titanic and Azada join Focus’ popular Revival range of super-budget price games and are available in a store near you.
Edraw Max enables students, teachers and business professionals to reliably create and publish kinds of diagrams to represent any ideas. With large pre-drawn libraries and more than 4600 vector symbols, drawing couldn't be easier!
New range of cards launched to make you the cover star.Hallmark Cards in partnership with OK Magazine has launched an exclusive and exciting new range of greeting cards that gives people the chance to give family and friends the A-List treatment.
Many people choose not to pursue an accident claim. The reasons range from knowing the insurance company will settle; to they don't want the legal hassles and expense.
Many individuals and businesses have always purchased their personal computers from a well-known provider to pre-conceived specifications. Increasingly...
The effectiveness of SEO and PPC Services are directly related to the quality and quantity of the performance data that they have to work with. If you are seeking assistance in achieving a higher ranking on search engine results, then we suggest you visit RankYourWebsites.com, specialist in this area. If you have found your attempts at optimization to prove fruitless, the representatives at RankYourWebsites.com will have a solution to increase your traffic.
http://www.vineyardsforsalein.com/ - online island vineyard for sale, vineyard for sale paso, texas vineyard for sale, washington vineyard for sale, tuscany vineyard for sale, vineyard for sale santa, vineyard for sale California
Mark Flanagan, Managing Director of Manchester health and safety, food safety and fire safety consultancy, Shieldyourself, discussed the Scores on the Doors scheme when he made a guest appearance on the BBC’s 5 Live Radio Show recently.
